A
38.02
-0.78 (-2.02%)
| Previous Close | 38.80 |
| Open | 38.60 |
| Volume | 847,602 |
| Avg. Volume (3M) | 1,424,662 |
| Market Cap | 4,628,934,656 |
| Price / Sales | 5.33 |
| Price / Book | 12.64 |
| 52 Weeks Range | |
| Earnings Date | 30 Oct 2024 - 4 Nov 2024 |
| Profit Margin | -52.94% |
| Operating Margin (TTM) | -14.75% |
| Diluted EPS (TTM) | -2.72 |
| Quarterly Revenue Growth (YOY) | 110.30% |
| Total Debt/Equity (MRQ) | 179.52% |
| Current Ratio (MRQ) | 5.08 |
| Operating Cash Flow (TTM) | -408.28 M |
| Levered Free Cash Flow (TTM) | -336.11 M |
| Return on Assets (TTM) | -21.51% |
| Return on Equity (TTM) | -109.19% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Apellis Pharmaceuticals, Inc. | Bearish | Bearish |
Stockmoo Score
0.9
| Analyst Consensus | 1.5 |
| Insider Activity | NA |
| Price Volatility | 2.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -2.5 |
| Average | 0.88 |
|
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 14.28% |
| % Held by Institutions | 97.25% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 92.00 (Baird, 142.01%) | Buy |
| Median | 74.00 (94.66%) | |
| Low | 35.00 (Scotiabank, -7.93%) | Hold |
| Average | 64.64 (70.04%) | |
| Total | 7 Buy, 4 Hold | |
| Avg. Price @ Call | 34.21 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Mizuho | 24 Oct 2024 | 38.00 (-0.04%) | Hold | 27.58 |
| 20 Sep 2024 | 39.00 (2.59%) | Hold | 32.51 | |
| Scotiabank | 16 Oct 2024 | 35.00 (-7.93%) | Hold | 27.95 |
| Wells Fargo | 24 Sep 2024 | 43.00 (13.11%) | Hold | 30.75 |
| Baird | 23 Sep 2024 | 92.00 (142.01%) | Buy | 32.72 |
| 09 Aug 2024 | 96.00 (152.53%) | Buy | 37.01 | |
| Needham | 20 Sep 2024 | 85.00 (123.60%) | Buy | 32.51 |
| 09 Aug 2024 | 85.00 (123.60%) | Buy | 37.01 | |
| JP Morgan | 13 Sep 2024 | 57.00 (49.94%) | Buy | 37.62 |
| 13 Aug 2024 | 64.00 (68.35%) | Buy | 35.72 | |
| Goldman Sachs | 09 Aug 2024 | 74.00 (94.66%) | Buy | 37.01 |
| 02 Aug 2024 | 66.00 (73.62%) | Buy | 36.56 | |
| UBS | 09 Aug 2024 | 83.00 (118.33%) | Buy | 37.01 |
| Wedbush | 09 Aug 2024 | 41.00 (7.85%) | Hold | 37.01 |
| HC Wainwright & Co. | 02 Aug 2024 | 83.00 (118.33%) | Buy | 36.56 |
| Jefferies | 31 Jul 2024 | 80.00 (110.44%) | Buy | 39.60 |
| Show more | ||||
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |